KR890002070B1 - Process for preparing thrombins - Google Patents

Process for preparing thrombins Download PDF

Info

Publication number
KR890002070B1
KR890002070B1 KR1019870003790A KR870003790A KR890002070B1 KR 890002070 B1 KR890002070 B1 KR 890002070B1 KR 1019870003790 A KR1019870003790 A KR 1019870003790A KR 870003790 A KR870003790 A KR 870003790A KR 890002070 B1 KR890002070 B1 KR 890002070B1
Authority
KR
South Korea
Prior art keywords
thrombin
solution
added
blood
prothrombin
Prior art date
Application number
KR1019870003790A
Other languages
Korean (ko)
Other versions
KR880012237A (en
Inventor
박영일
Original Assignee
이연합성약품공업 주식회사
유성락
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이연합성약품공업 주식회사, 유성락 filed Critical 이연합성약품공업 주식회사
Priority to KR1019870003790A priority Critical patent/KR890002070B1/en
Publication of KR880012237A publication Critical patent/KR880012237A/en
Application granted granted Critical
Publication of KR890002070B1 publication Critical patent/KR890002070B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue

Abstract

50 Liter of bovine serum was treated with 2kg BaSO4 and stood overnight at 4≰C. The resulting precipitate was treated with Nacitrate contg. 0.45% NaCl and centrifuged continuously at 2,000 rpm to give barium sulfate cake. After concentrating by dialysis or ultrafiltration, the concentrate was mixed with 1M Tris-HCl (pH 7.2) buffer, 1M CaCl2 and 6M NaCl. The soln. was stirred with thromboplastin for activation of thrombin, centrifuged at 8,000 rpm and trated with 490g (NH4)2SO4 to the filtrate to give a product.

Description

트롬빈의 제조방법Method of manufacturing thrombin

본 발명은 지혈제로 탁월한 효능을 가지는 트롬빈 제조방법에 관한 것이다.The present invention relates to a method for producing thrombin having excellent efficacy as a hemostatic agent.

외상이나, 수술시, 혈우병 또는 기타 출혈시 혈액의 손실방지는 대단히 중요한 문제이다.Preventing blood loss during trauma, surgery, hemophilia or other bleeding is a very important issue.

혈관밖에서 노출된 혈액이 응고하는 과정은 매우 복잡한 기작(Clotting mechanism)을 통하여 일어난다. 이 기작에는 여러 단백질 요소들이 효소나 조효소로 작용하며, 그 외에 Ca++이온, 인지질, 트롬보프라스틴 등이 필요한 것으로 알려져 있으며, 이러한 기작의 최종 단계로 프로트롬빈에서 일부 펩타이드가 분리되어 트롬빈의 만들어지는 과정이며, 바로 이 트롬빈이 피속에 녹아있고 단백질로서는 가장 많은 피브리노겐에 작용하여 피브리노겐의 C-말단부위의 일부 펩타이드를 떼어내어 피브린 단일체를 만드는데 이것이 생성되자마자 정전기적인 인력에 의하여 사슬처럼 연결되어 피브린크로트(clot)를 형성하여 혈액을 응고시켜 지혈시키는 것이다.The clotting process of blood exposed outside the blood vessel occurs through a very complex plotting mechanism. In this mechanism, several protein elements act as enzymes or coenzymes, and Ca + ions, phospholipids, and thromboprastin are known to be required. As a final step, some peptides are separated from prothrombin to form thrombin. This thrombin is dissolved in the blood and acts on the most fibrinogen as a protein to remove some of the peptides at the C-terminus of the fibrinogen to form a fibrin monolith. A crot is formed to coagulate blood and hemostasis.

현재 사용되는 지혈제로는 여러 종류의 제제가 있으나, 그 중 좋은 제제는 트롬빈 제제이다. 트롬빈 제제는 오래전부터 사용되어 왔으나, 그 제조공정이 대단히 복잡하고 제조원가가 높아서 널리 사용되고 있지 않다.There are several types of hemostatic agents currently used, but a good one is thrombin. Thrombin formulations have been used for a long time, but they are not widely used because of their high complexity and high manufacturing cost.

예를들면, 미국특허 제2,398,077호에서는 소의 혈액에 포타슘옥사레이트용액을 가하여 혈구등을 제거하고 원심분리하여 얻어진 혈장에 증류수를 약 10배량 가하고, 초산으로 pH를 5.2-5.4로 조절하고 원심분리하여 얻어진 수산화 혈장을 수산화마그네슘을 가하고 여기에 물을 가하고 가압 용기에 넣은 후 가압하에서 탄산가스를 가하여 프로트롬빈을 얻고, 이를 투석하여 마그네슘 이온을 제거하고 pH를 5.3로 조절하여 프로트롬빈 용액에 칼슘염을 가하여 앤티트롬빈이 제거된 활성화 트롬빈 용액을 얻고 여기에 물과 혼화성인 유기용매를 가하여 얻어진 침전을 물에 용해하고 얻어진 상증액에 유기용매를 가하고 진공 건조시켜서 트롬빈을 얻고 있다.For example, in US Patent No. 2,398,077, potassium oxalate solution is added to bovine blood to remove blood cells and centrifuged, and about 10-fold distilled water is added to the plasma obtained by centrifugation. Magnesium hydroxide was added to the obtained plasma and water was added thereto, followed by placing in a pressurized vessel, and carbon dioxide gas was added under pressure to obtain prothrombin. The dialysis was removed to remove magnesium ions, and the pH was adjusted to 5.3 to add calcium salt to the prothrombin solution. Thrombin is obtained by obtaining an activated thrombin solution from which thrombin has been removed, and adding the organic solvent which is miscible with water thereto, dissolving the precipitate in water, and adding the organic solvent to the obtained supernatant and vacuum drying.

그러나, 이 방법은 수십 단계의 공정을 가쳐야 하며, 더구나, 이러한 복잡한 과정을 거쳐서도 순수한 트롬빈을 얻기가 어려웠으며, 그 수율도 극히 낮아서, 트롬빈 제품을 대량으로 얻을 수 없었다.However, this method has to go through several tens of steps, and moreover, even through this complicated process, it is difficult to obtain pure thrombin, and the yield is extremely low, and a large quantity of thrombin products cannot be obtained.

본 발명자는 이러한 문제점을 해결하기 위하여 오랜 연구를 행한 결과 소의 수산화 혈장에 황산바륨을 가하여, 흡착시키고 구연산소다로 용출시키면 간편한 조작으로 고순도 및 고수율로 트롬빈을 생산할 수 있는 눌라운 사실을 발견하여 본 발명을 완성하게 되었다. 따라서 본 발명의 목적은 트롬빈 제제를 제조하는 신규의 개량된 제조방법에 관한 것이다.The present inventors have conducted a long study to solve this problem, and found that the addition of barium sulfate to bovine hydroxide plasma, adsorbing and eluting with sodium citrate, can produce thrombin with high purity and high yield with a simple operation. The invention was completed. The object of the present invention therefore relates to a novel and improved process for producing thrombin formulations.

본 발명을 상세히 설명하면 다음과 같습니다.The present invention is described in detail as follows.

1단계, 소의 혈액에서 혈장의 분리:소의 혈액이 혈관밖으로 노출되면 즉시 인트린식 패스웨이(Intrinsic Pathway)에 의한 응고 기작이 시작되며, 따라서 프로트롬빈이 트롬빈으로 바뀌면서 혈액이 응고된 덩어리가 생기게 된다. 소의 혈액을 죽은 소에서 받아내는 즉시 킬레이트화제인 수산나트륨 용액과 섞어 주어야 한다. 죽은지 1 분 내지 2분내의 소에서 혈액을 받아 혈액 9부피에 1부피의 비(V/V)로 2.5% 수산나트륨 용액과 잘 섞어준다. 이때 용기를 스테인레스 용기를 사용하고 혈액을 받으면서 서서히 저어주어 수산나트륨 용액와 충분히 섞이게 하는 것이 좋다. 수산염 처리된 혈액을 연속원심분리기를 이용하여 혈구세포를 제거하고 혈장을 얻는다. 이때 전체 피부피의 반 정도가 혈장으로 얻어진다.Stage 1, Separation of Plasma from Bovine Blood: Exposing the blood of a bovine out of blood vessels immediately initiates a coagulation mechanism by the Intrinsic Pathway, which causes prothrombin to turn into thrombin, resulting in a clogged mass of blood. As soon as the blood of a cow is taken from a dead cow, it must be mixed with a solution of sodium hydroxide, a chelating agent. Take blood from cattle within 1 to 2 minutes of death and mix well with 2.5% sodium hydroxide solution in 9 volumes of blood (V / V). At this time, it is good to use a stainless container and stir slowly while receiving the blood and mix well with sodium hydroxide solution. Oxalate treated with oxalate is removed from blood cells using a serial centrifuge to obtain plasma. At this time, about half of the skin is obtained in plasma.

2단계, 바륨설페이트에의 흡착과 용출:1단계에서 얻은 혈장에 1ℓ당 25-40g의 BaSo4를 천천히 가하면서 저어준다. BaSo4를 가한 후 모타가 장치된 교반기를 이용하여 서서히 저어준다. 이때 온도는 4℃ 하에서 실시하고 거품이 생기는 것은 피하는 것이 좋다. 이때 BaSo4에는 프롬트롬빈, 인자 VII, 인자 IX, 인자 X가 흡착하게 되고 그 이외의 단백질등은 BaSo4에 흡착치 못한다. 이렇게 얻은 BaSo4혼탄액을 일정 시간 저어준 후 수시간 냉소에서 방치하여 여러 단백질이 흡착된 BaSo4를 가라 앉힌다. 이렇게 얻은 BaSo4침전에 0.45% NaCl(W/v)이 포함된 구연산나트륨 용액을 최종농도 1mM되도록 넣어 저어주면서 혼탁시키고 BaSo4침전을 세척한다. 그 후 연속 원심분리기를 이용하여 BaSo4침전을 회수하고 위에서 언급한 세척을 2-3회 반복한다. 세척된 BaSo4에서 다시 모아 100mM 구연산나트륨을 가하여 적당한 시간동안 BaSo4가 현탁된 상태에서 저어준다. 이렇게 되면, BaSo4에 부착되어 있던 단백질이 용액중으로 용출되며, 이때 프로트롬빈도 함께 용액중으로 용출된다. 이 현탁액을 원심분리하여 프로트롬빈등이 용출된 용액을 회수한다. 이때 BaSo4가 환전히 제거되어야 한다.Adsorption and elution on barium sulphate in step 2, stir while slowly adding 25-40 g of BaSo 4 per liter to the plasma obtained in step 1. Add BaSo 4 and stir slowly using a motor-stirred stirrer. At this time, the temperature is carried out under 4 ℃, it is good to avoid the foaming. The BaSo 4 has prompted thrombin, factor VII, factor IX, factor X has been adsorbed the protein other than such value is not adsorbed on BaSo 4. The BaSo 4 mixed carbon solution thus obtained was stirred for a certain time, and left in a cool place for several hours to sink BaSo 4 adsorbed with various proteins. The BaSo 4 precipitate thus obtained was clouded with stirring by adding 0.45% NaCl (W / v) sodium citrate solution to a final concentration of 1 mM and washing the BaSo 4 precipitate. The BaSo 4 precipitate is then recovered using a continuous centrifuge and the washing mentioned above is repeated 2-3 times. Re-collect in washed BaSo 4 and add 100 mM sodium citrate and stir in suspension with BaSo 4 for a suitable time. This causes the protein attached to BaSo 4 to be eluted into solution, with prothrombin also eluting into solution. The suspension is centrifuged to recover a solution of prothrombin and the like. At this time, BaSo 4 should be removed.

3단계, 프로트롬빈의 트롬빈으로 활성화:2단계에서 얻은 용액내에 있는 높은 농도의 구연산 이온을 투석이나 울트라필트레이션(Ultrafiltration)을 이용하여 10-3M 이하로 낮춘다. 이렇게 구연산 이온 농도를 줄인 용출용액에 pH 7.2가 되도록 20mM Tris 용액(150mM NaCl과 20mM CaCl2가 함유된)으로 바꾼후 소의 뇌에서 분리한 트롬보프라스틴을 가하여 프로트롬빈을 트롬빈으로 활성화시킨다. 이때 온도가 높을수록 활성화에 유리하나 단백질이 안정을 위해 낮은 온도에서 장시간 모타가 부착된 교반기에서 방치한다.Step 3, Activate thrombin of prothrombin: Lower the high concentration of citrate ions in the solution obtained in step 2 below 10 -3 M using dialysis or ultrafiltration. The elution solution with reduced citric acid ion concentration was changed to 20 mM Tris solution (containing 150 mM NaCl and 20 mM CaCl 2 ) to pH 7.2, followed by addition of thromboprastin isolated from bovine brain to activate prothrombin with thrombin. At this time, the higher the temperature, the better the activation, but the protein is left in the stirrer attached to the motor for a long time at a low temperature to stabilize.

4단계, 트롬빈의 황산암모늄으로 분획화:3단계에서 프로트롬빈에서 트롬빈으로의 활성화가 끝난 용액에서 침전등을 원심분리를 이용하여 제거한다. 제거된 용액에 잘게 부순(NH4)2SO4를 40% 포화도까지 서서히 저어주면서 가한 후 적당시간동안 냉소에서 방치한다. 방치된 용액을 원심분리하여 침전을 제거하고 얻은 용액에 다시 (NH4)2SO4를 75% 포화도에 이르도록 가하고 다시 방치한 후 침전을 원심분리하여 회수한다. 회수된 침전을 50mM 글라이신과 20mM CaCl2용액에 녹인 후 투석막을 이용하여 투석한다. 이렇게 얻은 용액에 글라이신과 CaCl2를 적량 가하여 단백질과 염등으 비율을 맞춘다.Step 4 Fractionation of thrombin with ammonium sulfate: In step 3, the precipitates are removed from the solution from the activated prothrombin to thrombin by centrifugation. Crushed (NH 4 ) 2 SO 4 was added to the removed solution with gentle stirring to 40% saturation, and then left to cool for an appropriate time. The precipitated solution is centrifuged to remove the precipitate, and the resulting solution is again added with (NH 4 ) 2 SO 4 to reach 75% saturation, left to stand again, and the precipitate is recovered by centrifugation. The recovered precipitate is dissolved in 50mM glycine and 20mM CaCl 2 solution and dialyzed using a dialysis membrane. Glycine and CaCl 2 are added to the solution so that the ratio between protein and salt is adjusted.

5단계, 멸균 및 동결건조:위의 용액을 높이가 낮고 바닥이 넓으며 바닥 표면이 반사할 수 있는 접시나 그릇에 담고 살균 U.V 등 하에서 30분간 조사한다. 이때 담겨있는 용액의 깊이는 1cm 정도면 좋다. 그 후 퍼머롤(PhermerolR:염화벤조토늄)을 소량의 증류수에 녹여 고온, 고압 멸균한 후 일정비율(단백질:Phermerol=100:1)를 잘 섞어준 후 미리 멸균된 바이알에 적당량을 Unit씩 트롬빈 용액을 나눠 담은 후 무균 조건에서 동결건조한다.Step 5, Sterilization and lyophilization: Place the above solution in a dish or bowl of low height, wide bottom and reflective bottom surface and irradiate for 30 minutes under sterile UV light. At this time, the depth of the contained solution should be about 1cm. Then, permerol (Phermerol R : benzotonium chloride) is dissolved in a small amount of distilled water, and sterilized at high temperature and high pressure. After mixing a certain ratio (protein: Phermerol = 100: 1), a suitable amount of thrombin in a pre-sterilized vial is added. The solution is divided and lyophilized under aseptic conditions.

다음에 실시예로서 본 발명을 상세히 설명한다.Next, the present invention will be described in detail by way of examples.

[실시예]EXAMPLE

1. 소의 혈액에서 혈장의 분리:신선한 소의 혈액 90ℓ에 2.5% 수산화나트륨 10ℓ를 가하고 잘 교반한다. RPM 5000에서 원심분리하여 혈구세포를 제거하고 혈장 약 50ℓ를 얻는다.Separation of Plasma from Bovine Blood: Add 10 l of 2.5% sodium hydroxide to 90 l of fresh bovine blood and stir well. Centrifugation at RPM 5000 removes the blood cells and yields approximately 50 L of plasma.

2. 바륨설페이트에 의한 흡착과 용출:제1단계에서 얻어진 혈장에 바륨설페이트 2kg을 가하고 30분간 자기교반기로 서서히 교반하여 현탁액을 얻는다.2. Adsorption and elution by barium sulphate: 2 kg of barium sulphate is added to the plasma obtained in the first step, and the mixture is stirred slowly with a magnetic stirrer for 30 minutes to obtain a suspension.

이 현탁액을 4℃에서 하룻밤 방치한 다음 상증액을 제거한다. 상증액을 제거한 바륨설페이트에 0.45%의 염화나트륨을 함유하는 구연산나트륨 용액을 가하여 구연산나트륨의 양이 1mM되도록 하여 pH를 7.2로 조절한 다음 30분간 서서히 교반하고 RPM 2000에서 연속 원심분리하여 바륨설페이트 케이크를 얻는다.The suspension is left at 4 ° C. overnight and then the supernatant is removed. Sodium citrate solution containing 0.45% sodium chloride was added to the barium sulfate from which the supernatant was removed to adjust the pH to 7.2 mM sodium citrate. The pH was adjusted to 7.2. The mixture was stirred slowly for 30 minutes and continuously centrifuged at RPM 2000 to prepare the barium sulfate cake. Get

바륨설페이트 케이크를 0.45%의 염화나트륨을 함유하는 1mM 구연산나트륨 용액으로 2회 세척한다.The barium sulfate cake is washed twice with 1 mM sodium citrate solution containing 0.45% sodium chloride.

얻어진 바륨설페이트 케이트에 0.1M 구연산나트륨을 전체 혈장의 약 1/20량(V/V)을 가하여 pH를 5.8로 조절한 후 자기 교반기로 30분간 교반하여 현탁액을 얻는다.0.1 M sodium citrate was added to the obtained barium sulphate solution to adjust the pH to 5.8 by adding about 1/20 of the total plasma (V / V), followed by stirring for 30 minutes with a magnetic stirrer to obtain a suspension.

2000rpm으로 4℃에서 30분간 원심분리하여 상증액을 수집하고 상기 조작을 2회 반복하여 용출액을 얻고 상기 상증액과 합한다.Centrifuge for 30 minutes at 4 ° C. at 2000 rpm to collect supernatant and repeat the above procedure twice to obtain an eluate and combine with the supernatant.

3. 프로트롬빈의 트롬빈으로 활성화:2단계에서 얻어진 용액내에 잔존하는 구연산 이온을 투석이나 울트라필트레이션을 행하여 구연산 이온의 농도를 10-3M 이하로 낮춘 후, 투석액을 약 2ℓ로 농축한다. 이 농축액에 1M 트리스-HCl(pH7.2) 40ml, 1M CaCl2·40ml 및 6M NaCl 50ml를 가하고 소의 뇌에서 추출한 트롬보프라스틴을 소량 가하고 서서히 교반한다. 4℃에서 15시간 배양하여 프로트롬빈을 트롬빈을 활성화시킨다.3. Activation with thrombin of prothrombin: The citrate ions remaining in the solution obtained in step 2 are subjected to dialysis or ultrafiltration to reduce the concentration of citrate ions to 10 −3 M or less, and then the dialysis solution is concentrated to about 2 L. 40 ml of 1 M Tris-HCl (pH 7.2), 40 ml of 1 M CaCl 2 , and 50 ml of 6 M NaCl were added to the concentrate, and a small amount of thromboprastin extracted from bovine brain was added and stirred slowly. Incubate at 4 ° C. for 15 hours to activate thrombin for prothrombin.

4. 트롬빈의 활산암모늄으로 분획화:3단계에서 얻어진 활성화 트롬빈 용액을 4℃에서 8000rpm으로 원심분리하여 침전물을 제거하고 여기에 황산암모늄 490g을 천천히 가하고 4℃에서 2시간 자기 교반기로 서서히 교반하여 방치한다.4. Fractionation of thrombin with ammonium active acid: The activated thrombin solution obtained in step 3 was centrifuged at 8000 rpm at 4 ° C. to remove the precipitate, and slowly added 490 g of ammonium sulfate and stirred with a magnetic stirrer at 4 ° C. for 2 hours. do.

침전을 5000rpm으로 30분간 원심분리하여 얻고 다시 여액에 황산암모늄 550g을 가하고 5시간 교반한 후 8000rpm으로 30분간 원심분리하여 침전을 얻는다. 침전을 합하고 10mM CaCl2를 함유하는 50mM 글라이신 200ml에 용해시킨다.(pH 7.2).The precipitate was obtained by centrifugation at 5000 rpm for 30 minutes, and 550 g of ammonium sulfate was added to the filtrate and stirred for 5 hours, followed by centrifugation at 8000 rpm for 30 minutes to obtain a precipitate. The precipitates are combined and dissolved in 200 ml of 50 mM glycine containing 10 mM CaCl 2 (pH 7.2).

이 액을 증류수 25배량으로 투석한 후, 투석을 3회 반복한다. 투석 후 얻어진 용액을 글라이신과 CaCl2를 적당량 가하여 염비율을 2:1(W/W)로 조절한다.After dialysis this liquid with 25 times of distilled water, dialysis is repeated 3 times. After the dialysis, an appropriate amount of glycine and CaCl 2 is added to adjust the salt ratio to 2: 1 (W / W).

5. 멸균 및 동결 건조:4단계에서 얻어진 용액을 바닦면이 넓고 표면이 반사할 수 있는 용기에 넣고 UV 등으로 30분간 조사한다.5. Sterilization and freeze drying: Put the solution obtained in step 4 into a container with a large surface and reflect the surface and irradiate with UV etc. for 30 minutes.

여기서 퍼머롤(염화벤조토늄)을 넣고 (단백질 100mg당 1mg) 121℃에서 15psi 압력으로 15분간 멸균한 후 바이알에 충진한 후 동결건조시켜서 제품을 제조한다.Here, the permerol (benzotonium chloride) is added (1 mg per 100 mg of protein) and sterilized for 15 minutes at 15 psi pressure at 121 ° C., filled in vials, and lyophilized to prepare a product.

Claims (1)

소의 혈액에 수산화나트륨을 가하여 분리한 혈장에 황산바륨을 가하여 프로트롬빈을 흡착시킨 후 구연산나트륨으로 용출시키고 여기에 소의 뇌에서 추출한 트롬보프라스틴을 가하여 프로트롬빈을 트롬빈으로 활성화시킨 다음 황산암모늄으로 분획화하여 트롬빈을 제조하는 방법.Sodium hydroxide was added to bovine blood and barium sulfate was added to adsorbed plasma to adsorb prothrombin, eluted with sodium citrate, and thromboprastin extracted from bovine brain was added to activate prothrombin with thrombin and fractionated with ammonium sulfate. How to make thrombin.
KR1019870003790A 1987-04-21 1987-04-21 Process for preparing thrombins KR890002070B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019870003790A KR890002070B1 (en) 1987-04-21 1987-04-21 Process for preparing thrombins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019870003790A KR890002070B1 (en) 1987-04-21 1987-04-21 Process for preparing thrombins

Publications (2)

Publication Number Publication Date
KR880012237A KR880012237A (en) 1988-11-26
KR890002070B1 true KR890002070B1 (en) 1989-06-16

Family

ID=19260854

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870003790A KR890002070B1 (en) 1987-04-21 1987-04-21 Process for preparing thrombins

Country Status (1)

Country Link
KR (1) KR890002070B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505698A (en) * 2015-02-06 2018-03-01 コウシュウ・バイオシール・バイオテック・カンパニー・リミテッドGuangzhou Bioseal Biotech Co., Ltd. Method for the preparation of thrombin

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505698A (en) * 2015-02-06 2018-03-01 コウシュウ・バイオシール・バイオテック・カンパニー・リミテッドGuangzhou Bioseal Biotech Co., Ltd. Method for the preparation of thrombin
EP3253870A4 (en) * 2015-02-06 2018-07-11 Guangzhou Bioseal Biotech Co., Ltd. Method for preparation of thrombin
US10538754B2 (en) 2015-02-06 2020-01-21 Omrix Biopharmaceuticals Ltd. Method for preparation of thrombin
EP3808841A1 (en) * 2015-02-06 2021-04-21 Guangzhou Bioseal Biotech Co., Ltd. Method for preparation of thrombin
AU2015381628B2 (en) * 2015-02-06 2021-07-15 Guangzhou Bioseal Biotech Co., Ltd. Method for preparation of thrombin

Also Published As

Publication number Publication date
KR880012237A (en) 1988-11-26

Similar Documents

Publication Publication Date Title
US5304372A (en) Process for preparing a human thrombin concentrate intended for therapeutic use
US5260420A (en) Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
US4297344A (en) Blood coagulation factors and process for their manufacture
US4160025A (en) Method of producing a blood-coagulation-promoting preparation from human blood plasma
US3842061A (en) Method for isolation of antithrombin from animal tissue materials by adsorption on sulfated carbohydrate gel
EP0378208B1 (en) Production method for protein-containing composition
JP2540541B2 (en) Method for producing factor V concentrate
EA002149B1 (en) Improved methods for processing activated protein c
CZ330992A3 (en) Thrombin and process for preparing thereof
AU2003244850B2 (en) Processes for the preparation of fibrinogen
IE63528B1 (en) Composition of anticoagulants
JPH0543688B2 (en)
US3849252A (en) Enzyme composition and process for the manufacture thereof
US4364861A (en) Blood-coagulation-promoting products and methods of preparing them
JPH0530811B2 (en)
EP0726076B1 (en) Method of stabilizing protein c or activated protein c and stabilized composition
EP0823476B1 (en) Method for activating prothrombin to thrombin
KR890002070B1 (en) Process for preparing thrombins
JPH0698791A (en) Method of severing protein by enzymatic decomposition and method for its use
AU749177B2 (en) Method for purifying thrombin substrates and/or inhibitors or method for eliminating the same
CN108660126A (en) A kind of preparation process of freeze dried human zymoplasm
CN112011527B (en) Preparation method of thrombin
KR100377279B1 (en) How to make thrombin
US2624691A (en) Fibrinolysin derived from blood and methods of obtaining the same
JPS59167519A (en) Removal of fibrinogen from mixed serum proteins with deactivated thrombin gel

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010616

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee